Voya Investment Management LLC lifted its stake in shares of Heska Corporation (NASDAQ:HSKA) by 15.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,002 shares of the medical research company’s stock after purchasing an additional 395 shares during the period. Voya Investment Management LLC’s holdings in Heska Corporation were worth $306,000 as of its most recent SEC filing.
Other institutional investors also recently modified their holdings of the company. OxFORD Asset Management LLP lifted its holdings in Heska Corporation by 18.1% in the second quarter. OxFORD Asset Management LLP now owns 26,640 shares of the medical research company’s stock valued at $2,719,000 after acquiring an additional 4,074 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Heska Corporation by 115.5% in the second quarter. Dimensional Fund Advisors LP now owns 120,174 shares of the medical research company’s stock valued at $12,266,000 after acquiring an additional 64,418 shares during the last quarter. Teachers Retirement System of The State of Kentucky acquired a new position in Heska Corporation in the second quarter valued at approximately $296,000. California Public Employees Retirement System lifted its holdings in Heska Corporation by 14.7% in the second quarter. California Public Employees Retirement System now owns 12,480 shares of the medical research company’s stock valued at $1,274,000 after acquiring an additional 1,600 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Heska Corporation by 31.7% in the second quarter. Vanguard Group Inc. now owns 461,841 shares of the medical research company’s stock valued at $47,141,000 after acquiring an additional 111,232 shares during the last quarter. Institutional investors and hedge funds own 78.58% of the company’s stock.
HSKA has been the topic of a number of recent analyst reports. B. Riley reiterated a “neutral” rating and issued a $85.00 price objective on shares of Heska Corporation in a report on Friday, July 28th. Aegis upped their price objective on Heska Corporation from $114.50 to $129.50 and gave the company a “buy” rating in a report on Tuesday, August 1st. Benchmark Co. upped their price objective on Heska Corporation from $106.00 to $120.00 and gave the company a “buy” rating in a report on Thursday, August 3rd. BidaskClub upgraded Heska Corporation from a “hold” rating to a “buy” rating in a report on Thursday, August 3rd. Finally, Zacks Investment Research upgraded Heska Corporation from a “hold” rating to a “buy” rating and set a $109.00 price objective on the stock in a report on Friday, August 4th. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $106.25.
Heska Corporation (NASDAQ:HSKA) opened at $84.68 on Wednesday. Heska Corporation has a 52 week low of $62.06 and a 52 week high of $115.00. The company has a market capitalization of $619.71, a price-to-earnings ratio of 44.79, a price-to-earnings-growth ratio of 2.28 and a beta of 0.83.
Heska Corporation (NASDAQ:HSKA) last released its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.03. Heska Corporation had a return on equity of 15.35% and a net margin of 10.67%. The company had revenue of $31.40 million for the quarter, compared to analysts’ expectations of $36.10 million. During the same period in the prior year, the firm earned $0.45 earnings per share. The firm’s revenue was down 6.0% compared to the same quarter last year. research analysts forecast that Heska Corporation will post 2.03 EPS for the current fiscal year.
In other Heska Corporation news, EVP Nancy Wisnewski sold 825 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $102.21, for a total transaction of $84,323.25. Following the transaction, the executive vice president now directly owns 38,114 shares in the company, valued at $3,895,631.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO John Mcmahon sold 2,608 shares of the company’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $101.17, for a total value of $263,851.36. Following the transaction, the chief financial officer now owns 193 shares in the company, valued at $19,525.81. The disclosure for this sale can be found here. 14.70% of the stock is owned by corporate insiders.
Heska Corporation Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corporation and related companies with MarketBeat.com's FREE daily email newsletter.